Cargando…

The lived experience of juvenile idiopathic arthritis in young people receiving etanercept

BACKGROUND: This study explores young people’s daily experiences of living with Juvenile Idiopathic Arthritis (JIA) and their thoughts, beliefs and feelings related to the biological drug Etanercept, prescribed as part of their treatment. METHODS: An Interpretive Phenomenological approach was used t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Livermore, P, Eleftheriou, D, Wedderburn, LR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828872/ https://www.ncbi.nlm.nih.gov/pubmed/27068023 http://dx.doi.org/10.1186/s12969-016-0083-7

Ejemplares similares

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)

The experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young people
por: Mulligan, Kathleen, et al.
Publicado: (2015)

Clinical remission in juvenile idiopathic arthritis after termination of etanercept
por: Postępski, Jacek, et al.
Publicado: (2012)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis
por: Maciejewska-Paszek, Izabela, et al.
Publicado: (2017)

Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
por: Öman, Anders, et al.
Publicado: (2021)

Developing and Evaluating JIApp: Acceptability and Usability of a Smartphone App System to Improve Self-Management in Young People With Juvenile Idiopathic Arthritis
por: Cai, Ran A, et al.
Publicado: (2017)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
por: Hunter, PJ, et al.
Publicado: (2008)

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
por: Trachana, M, et al.
Publicado: (2011)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Beukelman, Timothy, et al.
Publicado: (2021)

Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
por: Glaesener, Stephanie, et al.
Publicado: (2014)

Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Advances in the treatment of polyarticular juvenile idiopathic arthritis
por: Webb, Kate, et al.
Publicado: (2015)

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
por: Prince, FHM, et al.
Publicado: (2008)

In vitro effects of etanercept on the development of different T cell subsets in patients with juvenile idiopathic arthritis
por: Cimaz, Rolando, et al.
Publicado: (2011)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
por: Klotsche, Jens, et al.
Publicado: (2021)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

Current Developments in the Use of Biomarkers for Juvenile Idiopathic Arthritis
por: Duurland, Chantal L., et al.
Publicado: (2014)

Early Prediction of Clinical Response to Etanercept Treatment in Juvenile Idiopathic Arthritis Using Machine Learning
por: Mo, Xiaolan, et al.
Publicado: (2020)

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
por: Levälampi, Tiina, et al.
Publicado: (2023)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
por: Horneff, Gerd, et al.
Publicado: (2017)

Mapping the current psychology provision for children and young people with juvenile dermatomyositis
por: Livermore, Polly, et al.
Publicado: (2021)

Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
por: Susic, G, et al.
Publicado: (2008)

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?
por: Rossi, L, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy
por: Radziszewska, Anna, et al.
Publicado: (2014)

Correlation of ultrasonography synovitis with disease activity and clinical response to etanercept treatment in juvenile idiopathic arthritis patients
por: Zhou, Li, et al.
Publicado: (2019)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction
por: Wojdas, Magdalena, et al.
Publicado: (2022)

The effect of etanercept therapy on adrenal steroid metabolism in juvenile idiopathic arthritis: a steroid metabolomics approach
por: Aviel, Yonatan Butbul, et al.
Publicado: (2023)

Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis
por: Orsini, Sara Immacolata, et al.
Publicado: (2023)

Are parents' views about their child's treatment for juvenile idiopathic arthritis (JIA) related to evaluations of their child's quality of life (QoL)? – SPARKS CHARM study
por: Mulligan, K, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_av060uiv351ja31mqqus9mfls4